Global Multiple Myeloma Therapeutics Market
Sizing, Segmentation, & Growth Forecast (2025-2030)
Last updated: July 2026
Report Scope: The downloadable datasheet contains market sizes in USD for the period 2025-30.
Market Breakdown: Sizes and growth rates are broken down by geography and market segment (see below for details).
1. Summary
The Global Multiple Myeloma Therapeutics Market was valued at $28.5 bn. in 2025. During the forecast period 2025-2030, it is expected to grow at 6.8% CAGR, to an estimated market size of $39.6 bn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.
2. Market Definition
The global multiple myeloma therapeutics market encompasses the research, development, and commercialization of pharmaceutical treatments and clinical procedures designed to manage malignant plasma cell proliferation. The scope includes targeted therapies (monoclonal antibodies, proteasome inhibitors), immunomodulatory drugs (IMiDs), CAR T-cell therapies, chemotherapy, and supportive care, while excluding general oncology diagnostics not specific to hematological malignancies.
3. Trends & Demand Drivers
Several key trends are expected to significantly impact the Multiple Myeloma Therapeutics Market in the period 2025-30:
- The market is experiencing a rapid shift from triplet therapy to quadruplet regimens that incorporate anti-CD38 monoclonal antibodies in earlier lines of treatment.
- Advancements in CAR T-cell therapies and bispecific antibodies are revolutionizing outcomes for relapsed or refractory patients by targeting BCMA antigens.
- There is an increasing adoption of subcutaneous administration over intravenous dosing to improve clinic throughput and patient convenience.
- The integration of Artificial Intelligence and machine learning is accelerating drug discovery and enabling more precise, personalized treatment plans.
- Clinical focus is intensifying on Minimal Residual Disease (MRD) assessment as a primary metric for guiding treatment duration and predicting long-term remission.
- The aging global population remains a fundamental driver, as the incidence of multiple myeloma is significantly higher in individuals over the age of 65.
- High treatment costs and the financial burden of long-term maintenance therapy continue to act as significant restraints on global market access.
4. Market Breakdown
The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments:
Geographies
- North America
- Europe
- Asia-Pacific
- Rest of World
Segments
- Targeted Therapies (mAbs & PIs)
- Immunomodulatory Drugs (IMiDs)
- CAR-T & Cell-based Therapies
- Chemotherapy & Others